NYSE$CVS
CVS Health Corp · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
CVS Health's third quarter results reflected strong performance in Health Services and Pharmacy & Consumer Wellness, highlighting the need to address macro challenges in the Health Care Benefits segment.
CVS Health's total revenues for the third quarter increased by 6.3% to $95.4 billion. GAAP diluted EPS was $0.07, and adjusted EPS was $1.09. The results were impacted by charges related to premium deficiency reserves in the Health Care Benefits segment.
- Total revenues increased by 6.3% compared to the prior year, reaching $95.4 billion.
- GAAP diluted EPS was $0.07, and adjusted EPS was $1.09.
- Health Care Benefits segment recorded premium deficiency reserves of approximately $1.1 billion.
- Strong performance was noted in the Health Services and Pharmacy & Consumer Wellness segments.
Headline financials
Revenue & EPS history
CVS Health · Revenue · Quarterly
$95.4B
Revenue by segment
CVS Health · $102B total across 3 segments · Q3 2023
- Health Services$46.9B+8.5%45.9%
- Pharmacy & Consumer Wellness$28.9B+8.1%28.3%
- Health Care Benefits$26.3B+16.8%25.8%
Forward guidance
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the information under the headings “CEO Commentary” and “Financial Results Summary” and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
56%
41 / 73 earnings
Positive
+14.9%
Q4 2024
Best reaction
-18.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +14.3% | +19.1% | |
| Q4 2025 | -0.1% | +3.6% | +0.4% | |
| Q3 2025 | -1.9% | -4.6% | -2.2% | |
| Q2 2025 | -0.3% | +1.8% | +17.4% | |
| Q1 2025 | +4.1% | -0.7% | -4.0% | |
| Q4 2024 | +14.9% | +19.7% | +19.4% | |
| Q3 2024 | +3.1% | +0.8% | -0.1% | |
| Q2 2024 | -0.8% | -4.3% | -1.0% | |
| Q1 2024 | -18.5% | -17.3% | -12.0% | |
| Q4 2023 | +1.8% | +4.8% | +1.8% | |
| Q3 2023 | +0.9% | +3.0% | -0.8% | |
| Q2 2023 | +0.5% | -0.1% | -11.2% | |
| Q1 2023 | -5.5% | -4.2% | -3.8% | |
| Q4 2022 | +4.8% | +4.5% | -10.3% | |
| Q3 2022 | +3.4% | +6.9% | +8.4% | |
| Q2 2022 | +6.8% | +7.0% | +4.3% | |
| Q1 2022 | +1.8% | +3.0% | -1.1% | |
| Q4 2021 | -5.0% | -7.1% | -6.6% | |
| Q3 2021 | +3.7% | +2.9% | -0.3% | |
| Q2 2021 | -4.7% | -2.8% | +4.1% | |
| Q1 2021 | +6.9% | +9.6% | +12.1% | |
| Q4 2020 | -2.0% | -5.1% | +0.4% | |
| Q3 2020 | +10.0% | +13.2% | +21.3% | |
| Q2 2020 | -1.3% | +1.1% | -7.3% | |
| Q1 2020 | +0.4% | +4.3% | +11.7% | |
| Q4 2019 | -2.5% | -3.4% | -19.2% | |
| Q3 2019 | +6.6% | +6.6% | +11.9% | |
| Q2 2019 | +9.2% | +8.6% | +15.0% | |
| Q1 2019 | +4.3% | +4.1% | -3.7% | |
| Q4 2018 | -10.8% | -12.4% | -19.8% | |
| Q3 2018 | +6.9% | +8.3% | +3.9% | |
| Q2 2018 | +4.8% | +6.2% | +18.1% | |
| Q1 2018 | -8.4% | -9.2% | -5.8% | |
| Q4 2017 | -6.7% | -5.7% | -6.8% | |
| Q3 2017 | -0.4% | +2.5% | +3.1% | |
| Q2 2017 | +0.4% | +0.4% | +1.6% | |
| Q1 2017 | -2.8% | -1.1% | -4.5% | |
| Q4 2016 | +1.9% | +2.1% | +4.4% | |
| Q3 2016 | -8.2% | -10.0% | -6.3% | |
| Q2 2016 | +4.2% | +4.2% | -0.1% | |
| Q1 2016 | +2.4% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +3.0% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +2.6% | — | — | |
| Q4 2013 | +2.4% | — | — | |
| Q3 2013 | +3.0% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | +0.1% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | +2.9% | — | — | |
| Q4 2011 | -1.2% | — | — | |
| Q3 2011 | +6.3% | — | — | |
| Q2 2011 | -5.7% | — | — | |
| Q1 2011 | +3.9% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +3.2% | — | — | |
| Q2 2010 | -2.7% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -2.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -17.6% | — | — | |
| Q3 2009 | -17.6% | — | — | |
| Q4 2008 | +1.1% | — | — | |
| Q2 2008 | +1.1% | — | — | |
| Q2 2009 | +1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro